0 item $0.00

Cardiometabolic Imaging

Read more

Laboratory head

Close
i Profile of author
Professor Eylem Levelt

Head of Cardiometabolic Imaging

Phone:+61 8532 7890

Latest Achievements

British Cardiovascular Society Michael Davies Early Career Award (2024)

European Association of Cardiovascular Imaging (EACVI) Leaders of Tomorrow Fellowship Programme (2022–2024)

Winner, Women as One International Escalator Award, research (2022–2023)

European Society of Cardiology, Educational Grant for Clinical Trials MSc, University of Oxford (2021–2024)

Bernard and Joan Marshall Research Prize Competition finalist, British Society of Cardiovascular Research Autumn Meeting (2017)

Read full biography
Professor Eylem Levelt Head of Cardiometabolic Imaging
We are dedicated to improving cardiovascular outcomes for patients with diabetes through interdisciplinary multicentre collaborative efforts.

 

About the Cardiometabolic Imaging laboratory

The Baker Cardiometabolic Imaging lab focuses on better understanding the mechanisms of heart disease in patients with cardiometabolic conditions through application of cardiovascular magnetic resonance imaging (CMR) imaging and cardiac magnetic resonance spectroscopy (MRS) techniques, and the modification of cardiovascular disease risk by testing novel treatment strategies with randomised clinical trials while monitoring the heart’s response to treatment using CMR imaging and MRS biomarkers.

As well as targeting cardiovascular disease in early disease phenotypes such as adults with isolated type 2 diabetes or obesity without cardiovascular complications, we also investigate the combined impact of diabetes and common cardiovascular conditions such as valvular heart disease, particularly aortic stenosis and inherited cardiomyopathies, in adults who have comorbid diabetes.

Our research focuses on three categories:

  1. Technical development work to improve advanced CMR imaging and MR Spectroscopy techniques.
  2. Testing novel treatment strategies with randomised clinical trials by monitoring the heart’s response to treatment using CMR imaging and MR Spectroscopy biomarkers to tackle cardiovascular disease in patients with T2D.
  3. Improving maternal cardiometabolic health.
 

Support us

With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.

Find out more